Skip to main content
Toggle navigation
Search
Home
Icon Legend
Food/Drinks Available
CE's Available
Reception
Pre-registration Required
Livestreaming
Recorded Session
PHARMACY
Home
PHARMACY
PHARMACY
Type here to filter the list
(244) Impact of the Timing of Reculture After Inhaled Tobramycin for
Pseudomonas Aeruginosa
Eradication in Pediatric Cystic Fibrosis Patients
Favorite
(245) Safety of Inhaled Tobramycin for
Pseudomonas aeruginosa
Eradication in CF Patients Less than 1 Year of Age
Favorite
(246) Provider Practices in the Management of Pulmonary Exacerbations in the Era of Highly Effective Modulator Therapy
Favorite
(247) Impact of elexacaftor/tezacaftor/ivacaftor post-lung transplant on CFQ-R and SNOT-20 scores
Favorite
(248) Self-reported adherence with concomitant medications by adults with cystic fibrosis after starting elexacaftor/tezacaftor/ivacaftor therapy
Favorite
(249) Impact of Elexacaftor/tezacaftor/ivacaftor on
Pseudomonas aeruginosa
Acquisition and Chronic Infection at a Single Pediatric Cystic Fibrosis Center
Favorite
(250) Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey
Favorite
(251) Evaluation of Medication Electronic Monitoring Systems (MEMS®) in Adherence Measurement in the real world setting
Favorite
(252) Real World Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Decreasing Cystic Fibrosis Pulmonary Exacerbations in Health-System Based Specialty Pharmacy Patients
Favorite
(253) Change in liver biomarkers after introduction of elexacaftor/tezacaftor/ivacaftor: Results from a 12-month follow-up study in the national CF-cohort in Denmark
Favorite
(254) Patient perception of the impact of elexacaftor/tezacaftor/ivacaftor and the COVID-19 pandemic on physical and mental health
Favorite
(255) Real-world identification of hepatically adjusted Trikafta dosing trends at Atrium Health
Favorite
(256) Tobramycin Pharmacokinetic Differences in Patients After Initiation of Highly Effective Modulator Therapy
Favorite
(257) Rapid Health Decline in Young CFTR
G551D
Ferrets After Discontinuation of CFTR Modulator
Favorite
(258) Impact of Temporal Changes in CFTR Activity on Fertility, Conception, Pregnancy, and Lactation in CF Ferrets
Favorite
(259) A Pilot Study to Evaluate The Impact of the The Patch Cap®/Patch App® on Adherence to Vitamins and Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis
Favorite
(260) CFTR Modulator-Associated Liver Inflammation in Pediatric Cystic Fibrosis
Favorite
(261) Concentrations of elexacaftor/tezacaftor/ivacaftor across the cystic fibrosis population: interim analysis of the CHEC-Pharmacokinetics study
Favorite
(262) Implementation of a Comprehensive Pharmacy-Driven Immunization Program in a Pediatric Cystic Fibrosis Clinic
Favorite
(263) Pharmacogenomics in Cystic Fibrosis Patients: A Personalized Medicine Approach
Favorite
(264) Tobramycin pharmacodynamic optimization and impact on exposure and nephrotoxicity in children and young adult with Cystic Fibrosis
Favorite
